Boston Partners Acquires 468,977 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Boston Partners lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 562.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 552,392 shares of the biopharmaceutical company's stock after purchasing an additional 468,977 shares during the quarter. Boston Partners owned 0.42% of Halozyme Therapeutics worth $20,218,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $1,030,000. Harvey Capital Management Inc. acquired a new position in Halozyme Therapeutics during the 4th quarter worth about $5,918,000. Hsbc Holdings PLC lifted its position in Halozyme Therapeutics by 35.0% during the 3rd quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company's stock worth $3,006,000 after buying an additional 20,346 shares in the last quarter. Aurora Investment Counsel acquired a new position in Halozyme Therapeutics during the 3rd quarter worth about $1,347,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Halozyme Therapeutics during the 3rd quarter worth about $591,000. Institutional investors own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of several research reports. StockNews.com upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, February 23rd. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, May 7th. Benchmark reiterated a "buy" rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. TD Cowen started coverage on shares of Halozyme Therapeutics in a research report on Thursday, February 29th. They set an "outperform" rating and a $54.00 target price on the stock. Finally, JMP Securities cut their target price on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 8th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $53.14.

Halozyme Therapeutics Stock Down 0.9 %

NASDAQ HALO traded down $0.43 during trading hours on Thursday, reaching $45.39. 1,037,269 shares of the company's stock were exchanged, compared to its average volume of 1,212,260. The company's 50-day moving average is $40.47 and its two-hundred day moving average is $38.41. Halozyme Therapeutics, Inc. has a one year low of $31.86 and a one year high of $46.16. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64. The company has a market capitalization of $5.78 billion, a price-to-earnings ratio of 18.76, a price-to-earnings-growth ratio of 0.49 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The business had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares of the company's stock, valued at approximately $6,473,094.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 30,000 shares of company stock valued at $1,196,800. 2.70% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.